



ASX ANNOUNCEMENT

Shareholder webinar

- **Online presentation in conjunction with the open Retail Entitlement Offer**

Melbourne, VIC. (15 June 2022) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, is pleased to invite shareholders and other interested parties to a Shareholder Webinar hosted by Interim CEO Sam Lanyon.

The webinar will provide an overview of the Lumos Diagnostics business as part of the ongoing capital raising and Retail Entitlement Offer available to eligible shareholders.

The webinar will be held on Friday, 17 June 2022 at 10.30am AEST.

For the Q&A session, investors are invited to send questions prior to the webinar to matt@nwrcommunications.com.au.

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_ULxI6sMBSLG395kTIA-DIw

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

This announcement has been approved by the Lumos Disclosure Committee.

-Ends-

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumosbranded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598